TGFB1 and breast carcinoma: ALK5 and EW-7197 inhibitors reduce paclitaxel-promoting epithelial-mesenchymal transition and BCSC numbers, suggesting that combined treatment of paclitaxel with TGF-β inhibitors attenuate breast cancer metastasis and BCSCs (Park et al., 2015).